BioImpedentiometry, Lung UltraSound and cONgestion in Heart Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-31

Study Completion Date

2020-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to validate non-invasive and user-friendly methods to monitor systemic and pulmonary congestion in heart failure patients.

The primary objective is to validate the role of bioimpedentiometry, pulmonary and subcutaneous ultrasound, to assess changes in total body water in patients with heart failure. vs the gold standard technique of deuterium oxide dilution Secondary objectives are

\- to evaluate the applicability of bioimpedentiometry, pulmonary and subcutaneous ultrasound to monitor systemic, pulmonary and peripheral district congestion in relation with clinical and laboratory variables; 2)to analyze the organizational issues related to the use of these methods.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bedside Ultrasound-guided Volume Management and Discharge Timing for Patients With Heart Failure During Hospitalization: A Randomized Controlled Trial

NCT07046169

Acute Decompensated Heart Failure (ADHF)

ACTIVE_NOT_RECRUITING NA

IVC and Lung Ultrasound B-lines Guided Decongestion in Critically Ill ESKD Patients With Heart Failure

NCT06373575

End-stage Renal Disease

ENROLLING_BY_INVITATION NA

Diaphragmatic Echography in Critically Ill patientS

NCT02696018

Respiratory Failure

COMPLETED

Comparison Between Lung Ultrasound and Chest Radiography for Acute Dyspnea

NCT02105207

Dyspnea Congestive Heart Failure

COMPLETED NA

HF vs NIV in Acute Cardiogenic Pulmonary Edema

NCT05989139

Pulmonary Edema Cardiac Cause

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Increased congestion leads to the clinical manifestation of heart failure (dyspnea, peripheral edema) and is considered the leading cause of hospital admissions and death among patients with HF Preclinical recognition of congestion in HF patients through home monitoring is crucial to prevent acute exacerbations and hospital admissions. Daily body weight, vital signs and fluid balance give only an indirect assessment of the level of congestion.

Deuterium oxide dilution is the non-invasive reference method for total body water assessment.

Bioelectrical impedance analysis (BIA) and chest ultrasound are simple, non-invasive techniques potentially applicable for home monitoring of congestion by non-physicians.

BIA is a noninvasive method for the study of body composition based on the measurement of body electrical resistance; BIA may allow measurement of whole body and segmental, e.g. pulmonary, fluids. However data on the value of BIA for the monitoring of HF patients are still scarce, inconclusive and relative to small cohorts of patients.

Lung ultrasound (LUS) through evaluation of B-lines, reverberation artifacts in the presence of extravascular lung water has been proposed as a semiquantitative tool to assess pulmonary congestion. B lines showed a good correlation with multiple indicators of congestion.

The aim of this study is to validate whole body and segmental BIA and lung ultrasound vs the gold standard deuterium dilution technique to monitor changes in systemic and pulmonary congestion after treatment in the setting of acute heart failure (AHF Group 1) and advanced chronic heart failure (ad-CHF Group 3) using as controls stable chronic heart failure outpatients (CHF Group 2).

Enrolled patients will simultaneously undergo clinical assessment of congestion (weight gain, pulmonary rales, jugular venous pressure, peripheral edema, chest X-ray), routine laboratory, BIA and pulmonary and subcutaneous ultrasound and deuterium administration as follows Group 1 (Acute Heart Failure - AHF) Patients will be assessed within 24 hours of admission for acute heart failure (T0), and at hospital discharge after an average of 10 days (Td).

Group 2 (Chronic Heart Failure - CHF) Patients will be assessed during a programmed outpatient visit (T0) and after 10 ± 3 days (T1).

Group 3 (Advanced Chronic Heart Failure -Ad-CHF) Ad-CHF patients on periodic levosimendan undergo monthly levosimendan infusions in the outpatient clinic. Baseline assessments will be performed the day of levosimendan administration, before infusion start(T0) and after 80 +/- 12 hours, i.e at the peak haemodynamic effect of levosimendan (Tp).

In all patient groups, vital status and hospital admissions or emergency department visits and their cause will be assessed after 6 months by telephone follow-up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congestive Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Acute heart failure HF,Chronic HF,Advanced chronic HF

patient admitted to the hospital for acute heart failure (de-novo or exacerbation of chronic heart failure), for Chronic HF and for Advanced chronic heart failure

Group Type OTHER

Deuterium oxide dilution

Intervention Type OTHER

Reference standard for total body water: deuterium oxide dilution by mass spectrometry

Bioimpedentiometry

Intervention Type OTHER

Bioimpedentiometry: measurement of whole body and thoracic resistance and reactance

Lung and subcutaneous ultrasound

Intervention Type OTHER

Ultrasound: semiquantitative scoring of lung congestion (B lines) and peripheral edema (subcutaneous echography of the ankle)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Deuterium oxide dilution

Reference standard for total body water: deuterium oxide dilution by mass spectrometry

Intervention Type OTHER

Bioimpedentiometry

Bioimpedentiometry: measurement of whole body and thoracic resistance and reactance

Intervention Type OTHER

Lung and subcutaneous ultrasound

Ultrasound: semiquantitative scoring of lung congestion (B lines) and peripheral edema (subcutaneous echography of the ankle)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed informed consent

1. Group 1 (Acute Heart Failure - AHF), patient admitted to the hospital for acute heart failure (de-novo or exacerbation of chronic heart failure), who have at least two of the following congestion criteria:

* weight gain ≥ 2 kg over the three days prior to hospitalization
* physical findings or radiographic signs of pulmonary congestion (crackles, semi-orthopnea)
* Hepatomegaly \> 2 cm from the arch rib or ascites
* jugular turgor or central venous pressure \> 10 cm H20
* Ankle swelling
2. Group 2 (Chronic Heart Failure - CHF): outpatients with chronic heart failure (CHF) with characters of clinical stability

* No hospitalization in the previous six months
* Symptoms stable for at least 4 weeks
* Oral therapy stable for at least 4 weeks
* No involuntary weight variations greater than 2 kg in the last 4 weeks
* Absence of signs of congestion
3. Group 3 (advanced Chronic Heart Failure - ad-CHF) Patients on optimal medical therapy for HF and treated with periodic infusions of levosimendan (every 4 weeks) according to the following criteria

* Systolic dysfunction (LVEF \<35%)
* NYHA Class IIIb-IV and/or level INTERMACS 4, 5, 6
* ≥2 admissions or access to the emergency department for acute HF exacerbation in the previous 12 months

Exclusion Criteria

* Uremia in dialysis treatment
* Invasive mechanical ventilation
* Mechanical circulatory support
* Cardiac cachexia defined as weight loss ≥ 5% in the prior 12 months or body mass index \<20 kg/m2 and hypoalbuminemia (albumin \<3.2 g/dl) or anemia (hemoglobin \<12 g/l)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No